Orexo Healthcare Sweden


KEY DATA

Stock country Sweden ORX SS Bloombera ORX.ST Reuters Share price (close) SEK 46.00 Free Float 89% EUR 0.16/SEK 1.58 Market cap. (bn) Website www.orexo.com Next report date 29 Apr 2021

PERFORMANCE



VALUATION APPROACH



Source: Nordea estimates

ESTIMATE CHANGES

| Year | 2021E | 2022E | 2023E |
|------------|-------|-------|-------|
| Sales | -8% | -13% | -19% |
| EBIT (adj) | -138% | -80% | -68% |
| | | | |

Source: Nordea estimates

Nordea Markets - Analysts Klas Pyk Analyst

Slow start for Digital Therapies

Orexo's DTx launch has got off to a slow start, with close to no sales being reported in Q4 2020. We stand by our view that digital therapies in general should face a high underlying need, but we acknowledge that Orexo must soon overcome the current reimbursement challenges and show an uptick in DTx revenue in order for the market to regain confidence in the outlook and the stock. We take down our estimates and lower our DCF-based fair value range to SEK 72-91 (95-119) following the report.

Lower opex than expected, driven by slow start for DTx

Sales totalled SEK 159.2m in Q4 2020, down from SEK 238.1m in Q4 2019. Zubsolv sales declined by 15.9% y/y in local currency to SEK 143.1m, largely in line with our expectations. EBITDA was SEK 1m, compared to our forecast of SEK -100m, driven by lower-than-expected opex. Full-year opex totalled SEK 617m, significantly lower than the company's guidance of SEK 675-725m as of Q3 2020. The company attributes the low costs to a slow sales uptake for its recently launched DTx offering.

Reimbursement yet to be established

Even though the FDA has been agile in adapting to allow for digital therapies, payers have been slower. This has caused unexpectedly poor sales uptake for Orexo's DTx offering, according to the company, with close to no sales being reported in Q4 2020. It is clear to us that the reimbursement process will take longer than both we and the company had previously anticipated, and we therefore significantly lower our revenue estimates for 2021-23. We nevertheless stand by our view that digital therapies in general should face a high underlying need, supporting the long-term prospects.

Near-term wins are key for the share

We argue that it is key for Orexo to soon overcome the reimbursement challenges and show an uptick in DTx revenue in order for the market to regain confidence in the outlook and the stock, particularly considering the headwinds facing Zubsolv. We lower our estimates and also lower our DCF-based value range to SEK 72-91 (95-119) following the report.

| SUMMARY TABLE - KEY | SUMMARY TABLE - KEY FIGURES | | | | | | | | |
|--------------------------|-----------------------------|--------|-------|---------|---------|--------|--------|--|--|
| SEKm | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | 2023E | | |
| Total revenue | 644 | 783 | 845 | 664 | 633 | 751 | 857 | | |
| EBITDA (adj) | 78 | 117 | 224 | 19 | -183 | 55 | 110 | | |
| EBIT (adj) | 57 | 96 | 183 | -20 | -218 | 20 | 75 | | |
| EBIT (adj) margin | 8.9% | 12.2% | 21.6% | -3.0% | -34.5% | 2.7% | 8.7% | | |
| EPS (adj, SEK) | 0.67 | 3.92 | 4.82 | -2.45 | -5.66 | 0.49 | 1.84 | | |
| EPS (adj) growth | -20.5% | 485.5% | 23.0% | -150.8% | -131.0% | 108.7% | 275.1% | | |
| DPS (ord, SEK) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | |
| EV/Sales | 2.2 | 2.3 | 2.1 | 2.3 | 2.5 | 2.1 | 1.8 | | |
| EV/EBIT (adj) | 24.7 | 18.8 | 9.6 | n.m. | n.m. | 79.8 | 20.9 | | |
| P/E (adj) | 61.6 | 15.0 | 13.0 | n.m. | n.m. | 93.7 | 25.0 | | |
| P/BV | 4.3 | 4.4 | 3.1 | 3.1 | 4.3 | 4.1 | 3.6 | | |
| Dividend yield (ord) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | |
| FCF Yield bef A&D, lease | 4.3% | 11.7% | 13.1% | -10.1% | -17.3% | 0.5% | 4.0% | | |
| Net debt | -9 | -269 | -473 | -214 | 37 | 32 | -20 | | |
| Net debt/EBITDA | -0.1 | -2.3 | -2.1 | -11.4 | n.m. | 0.6 | -0.2 | | |
| ROIC after tax | 8.1% | 15.0% | 29.1% | -2.9% | -29.2% | 2.5% | 8.6% | | |

Detailed estimates

| OREXO: DETAILED ESTIMA | IES (SEKn | n) | | | | | | | | | | |
|---------------------------|-----------|-------|--------|--------|--------|--------|--------|--------|--------|--------|-------|-------|
| | | 202 | 20 | | | 202 | 21 | | | | | |
| SEKm | Q1 | Q2 | Q3 | Q4 | Q1E | Q2E | Q3E | Q4E | 2020 | 2021E | 2022E | 2023E |
| Net sales | 175 | 179 | 150 | 159 | 151 | 154 | 154 | 174 | 664 | 633 | 751 | 857 |
| Gross profit | 155 | 159 | 136 | 148 | 130 | 134 | 135 | 154 | 598 | 553 | 668 | 776 |
| Gross, margin | 88.6% | 88.9% | 90.4% | 92.9% | 86.0% | 86.0% | 86.0% | 86.0% | 90.1% | 86.0% | 85.0% | 85.0% |
| EBITDA | 39 | -9 | -12 | 1 | -38 | -40 | -61 | -44 | 19 | -183 | 55 | 110 |
| EBITDA margin, % | 22.3% | -5.0% | -8.1% | 0.6% | -25.1% | -25.9% | -39.9% | -25.2% | 2.8% | -28.9% | 7.3% | 12.8% |
| IP litigation costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EBITDA | 39 | -9 | -12 | 1 | -38 | -40 | -61 | -44 | 19 | -183 | 55 | 110 |
| Adjusted EBITDA margin, % | 22.4% | -5.0% | -8.1% | 0.6% | -25.1% | -25.9% | -39.9% | -25.2% | 2.8% | -28.9% | 7.3% | 12.8% |
| EBIT | 34 | -13 | -30 | -11 | -46 | -49 | -70 | -53 | -20 | -218 | 20 | 75 |
| EBIT margin | 19.4% | -7.4% | -19.7% | -6.9% | -30.9% | -31.6% | -45.6% | -30.3% | -3.0% | -34.5% | 2.7% | 8.7% |
| Net income | 83 | -33 | -85 | -50 | -41 | -43 | -63 | -47 | -84 | -194 | 17 | 63 |
| EPS | 2.3 | -0.9 | -2.4 | -1.4 | -1.2 | -1.3 | -1.8 | -1.4 | -2.5 | -5.7 | 0.5 | 1.8 |
| | | | | | | | | | | | | |
| Zubsolv US sales | 163.9 | 172.5 | 143.8 | 143.1 | 135.9 | 138.2 | 130.6 | 133.5 | 623.3 | 538.1 | 522.3 | 505.9 |
| Growth y/y, % | 1.4% | -6.5% | -21.3% | -24.9% | -17.1% | -19.9% | -9.2% | -6.7% | -13.3% | -13.7% | -2.9% | -3.1% |
| - of which organic, % | -4.0% | -8.7% | -14.9% | -15.7% | -2.7% | -5.4% | -2.5% | -3.0% | -11.4% | -8.2% | -2.9% | -3.1% |
| - of which FX, % | 5.4% | 2.2% | -6.4% | -9.2% | -14.4% | -14.5% | -6.7% | -3.7% | -1.9% | -5.5% | 0.0% | 0.0% |
| | | | | | | | | | | | | |

Valuation

Based on our updated forecasts, we derive a DCF-based fair value range of SEK 72-91 (95-119), using a WACC of 8-10%.

In our DCF model, we use our explicit forecasts for Orexo until 2025, plus a set of general assumptions until 2050, as outlined below. Our DCF model uses a stringent approach, with ROIC equalling WACC in the terminal period, preventing the model from extrapolating above-market returns in perpetuity.

| OREXO: DCF MODEL ASSUMPTIONS | | | | | | | |
|-----------------------------------|---------|---------|---------|---------|---------|---------|-------|
| | 2021-26 | 2027-31 | 2032-36 | 2037-41 | 2042-46 | 2047-51 | Sust. |
| Sales growth, CAGR | 19.5% | 4.0% | 3.0% | 2.5% | 2.5% | 2.5% | |
| EBIT-margin, excluding associates | 18.3% | 16.5% | 16.5% | 16.5% | 16.5% | 5.1% | |
| Capex/depreciation, x | 1.4 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | |
| Capex/sales | 4.6% | 4.6% | 4.6% | 4.6% | 4.6% | 4.6% | |
| NWC/sales | 28.8% | 30.0% | 30.0% | 30.0% | 30.0% | 30.0% | |
| FCFF, CAGR | -210.7% | -9.8% | 3.8% | 2.9% | 2.5% | -23.4% | 2.5% |

Source: Company data and Nordea estimates

DCF MODEL SENSITIVITY: SALES GROWTH AND EBIT MARGIN CHANGE (SEK/SHARE)

| | | | Sales gre | owth change | | |
|-------------|--------|--------|-----------|-------------|--------|--------|
| | | -1.0pp | -0.5pp | | +0.5pp | +1.0pp |
| | +1.0pp | 80 | 82 | 84 | 86 | 88 |
| EBIT margin | +0.5pp | 79 | 80 | 82 | 84 | 86 |
| change | | 77 | 79 | 80 | 82 | 84 |
| | -0.5pp | 76 | 77 | 78 | 80 | 82 |
| | -1.0pp | 74 | 75 | 77 | 78 | 80 |

Source: Company data and Nordea estimates

DCF MODEL SENSITIVITY: WACC AND SALES GROWTH CHANGE (SEK/SHARE)

| | | | , | WACC | | |
|--------------|--------|------|------|------|------|-------|
| | | 8.0% | 8.5% | 9.0% | 9.5% | 10.0% |
| | +1.0pp | 95 | 89 | 84 | 79 | 75 |
| Sales growth | +0.5pp | 93 | 87 | 82 | 77 | 73 |
| change | | 91 | 85 | 80 | 76 | 72 |
| | -0.5pp | 88 | 83 | 79 | 74 | 71 |
| | -1.0pp | 87 | 82 | 77 | 73 | 69 |

Source: Company data and Nordea estimates

DCF MODEL SENSITIVITY: WACC AND EBIT MARGIN CHANGE (SEK/SHARE)

| | | WACC | | | | | | | |
|-------------|--------|------|------|------|------|-------|--|--|--|
| | | 8.0% | 8.5% | 9.0% | 9.5% | 10.0% | | | |
| | +1.0pp | 95 | 89 | 84 | 79 | 75 | | | |
| EBIT margin | +0.5pp | 93 | 87 | 82 | 77 | 73 | | | |
| change | | 91 | 85 | 80 | 76 | 72 | | | |
| | -0.5pp | 88 | 83 | 78 | 74 | 70 | | | |
| | -1.0pp | 86 | 81 | 77 | 73 | 69 | | | |

Reported numbers and forecasts

| INCOME STATEMENT | | | | | | | | | | | |
|--|----------------|--------------|----------------|---------------------|--------------|----------------------|----------------|------------------|------------------|--------------|---------------|
| SEKm | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | 2023E |
| Total revenue | 429 | 570 | 643 | 706 | 644 | 783 | 845 | 664 | 633 | 751 | 857 |
| Revenue growth | 31.6% | 32.8% | 12.8% | 9.7% | -8.8% | 21.7% | 7.9% | -21.4% | -4.5% | 18.5% | 14.1% |
| of which organic | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| of which FX | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| EBITDA | -90 | -12 | -150 | 74 | 78 | 117 | 224 | 19 | -183 | 55 | 110 |
| Depreciation and impairments PPE | -5 | -5 | -4 | -5 | -4 | -4 | -8 | -31 | -19 | -19 | -19 |
| of which leased assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITA | -94 | -17 | -154 | 70 | 74 | 112 | 215 | -12 | -203 | 36 | 90 -16 |
| Amortisation and impairments EBIT | -46 -140 | -8 -25 | -15 -169 | -18 52 | -17 57 | -17 96 | -33 183 | -8 -20 | -16 -218 | -16 20 | 75 |
| of which associates | -140 | -23 | -109 | 0 | 0 | 0 | 0 | -20 | -210 | 0 | 0 |
| Associates excluded from EBIT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net financials | -14 | -28 | -22 | -16 | -28 | -4 | -3 | -18 | 3 | 0 | 0 |
| of which lease interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in value, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax profit | -153 | -53 | -191 | 36 | 30 | 92 | 179 | -38 | -216 | 20 | 74 |
| Reported taxes | -2 | -4 | -7 | -7 | -7 | 46 | -9 | -46 | 22 | -3 | -11 |
| Net profit from continued operations | -155 | -57 | -198 | 29 | 23 | 138 | 171 | -84 | -194 | 17 | 63 |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority interests | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit to equity | -155 | -57 | -198 | 29 | 23 | 138 | 171 | -84 | -194 | 17 | 63 |
| EPS, SEK | -4.87 | -1.73 | -5.74 | 0.84 | 0.67 | 3.92 | 4.82 | -2.45 | -5.66 | 0.49 | 1.84 |
| DPS, SEK | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| of which ordinary | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| of which extraordinary | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit margin in percent | | | | | | | | | | | |
| EBITDA | -20.9% | -2.2% | -23.4% | 10.5% | 12.1% | 14.9% | 26.5% | 2.8% | -28.9% | 7.3% | 12.8% |
| EBITA | -21.9% | -3.1% | -24.0% | 9.9% | 11.5% | 14.4% | 25.5% | -1.8% | -32.0% | 4.8% | 10.5% |
| EBIT | -32.5% | -4.4% | -26.2% | 7.3% | 8.9% | 12.2% | 21.6% | -3.0% | -34.5% | 2.7% | 8.7% |
| Adjusted earnings | | | | | | | | | | | |
| EBITDA (adj) | -90 | -12 | -150 | 74 | 78 | 117 | 224 | 19 | -183 | 55 | 110 |
| EBITA (adj) | -94 | -17 | -154 | 70 | 74 | 112 | 215 | -12 | -203 | 36 | 90 |
| EBIT (adj) | -140 | -25 | -169 | 52 | 57 | 96 | 183 | -20 | -218 | 20 | 75 |
| EPS (adj, SEK) | -4.87 | -1.73 | -5.74 | 0.84 | 0.67 | 3.92 | 4.82 | -2.45 | -5.66 | 0.49 | 1.84 |
| Adjusted profit margins in percent | | | | | | | | | | | |
| EBITDA (adj) | -20.9% | -2.2% | -23.4% | 10.5% | 12.1% | 14.9% | 26.5% | 2.8% | -28.9% | 7.3% | 12.8% |
| EBITA (adj) | -21.9% | -3.1% | -24.0% | 9.9% | 11.5% | 14.4% | 25.5% | -1.8% | -32.0% | 4.8% | 10.5% |
| EBIT (adj) | -32.5% | -4.4% | -26.2% | 7.3% | 8.9% | 12.2% | 21.6% | -3.0% | -34.5% | 2.7% | 8.7% |
| Performance metrics | | | | | | | | | | | |
| CAGR last 5 years | | | | | | | | | | | |
| Net revenue | n.a. | n.a. | n.a. | 28.7% | 14.6% | 12.8% | 8.2% | 0.6% | -2.1% | 3.1% | 1.8% |
| EBITDA | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | -6.7% | -1.2% |
| EBIT | n.a. | n.a. | n.a. | n.a. | n.m. | n.m. | n.m. | n.m. | n.m. | -18.9% | -4.9% |
| EPS | n.a. | n.a. | n.a. | n.a. | n.m. | n.m. | n.m. | n.m. | n.m. | -6.0% | -14.0% |
| DPS | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. |
| Average last 5 years | | | | | | | | | | | |
| Average EBIT margin | n.a. | n.a. | n.a. | -13.5% | -7.5% | 0.3% | 6.0% | 10.1% | 2.7% | 1.6% | 1.0% |
| Average EBITDA margin | n.a. | n.a. | -14.5% | -9.0% | -3.3% | 3.2% | 9.5% | 14.1% | 7.1% | 6.3% | 6.0% |
| VALUATION RATIOS - ADJUSTED | | | | | | | | | | | |
| SEKm | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | 2023E |
| P/E (adj) | n.m. | n.m. | n.m. | 44.7 | 61.6 | 15.0 | 13.0 | n.m. | n.m. | 93.7 | 25.0 |
| EV/EBITDA (adj) | n.m. | n.m. | n.m. | 19.0 | 18.2 | 15.5 | 7.8 | 80.1 | n.m. | 29.2 | 14.2 |
| EV/EBITA (adj) | n.m. | n.m. | n.m. | 20.3 | 19.2 | 16.0 | 8.1 | n.m. | n.m. | 44.8 | 17.2 |
| EV/EBIT (adj) | n.m. | n.m. | n.m. | 27.4 | 24.7 | 18.8 | 9.6 | n.m. | n.m. | 79.8 | 20.9 |
| VALUATION RATIOS - REPORTED SEKm | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | 2023E |
| P/E | | | | 2016 44.7 | 61.6 | 2 018 15.0 | 13.0 | | | 93.7 | 2023E 25.0 |
| EV/Sales | n.m. 12.46 | n.m. 8.14 | n.m. 3.82 | 2.01 | 2.21 | 2.30 | 2.07 | n.m. 2.27 | n.m. 2.55 | 2.14 | 1.82 |
| EV/Sales EV/EBITDA | | | | 19.0 | 18.2 | 2.30 15.5 | 7.8 | 80.1 | 2.55 n.m. | 2.14 | 1.02 |
| EV/EBITA | n.m. n.m. | n.m. n.m. | n.m. n.m. | 20.3 | 19.2 | 16.0 | 8.1 | n.m. | n.m. | 44.8 | 17.2 |
| EV/EBIT | n.m. | n.m. | n.m. | 27.4 | 24.7 | 18.8 | 9.6 | n.m. | n.m. | 79.8 | 20.9 |
| _ v/UII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Dividend vield (ord) | | | | | 0.070 | 0.070 | 0.070 | 0.070 | 0.070 | 0.070 | |
| Dividend yield (ord.) FCF yield | | | | | 4 2% | 11 4% | 11 9% | -10.0% | -17.3% | 0.5% | 4 0% |
| Dividend yield (ord.) FCF yield FCF Yield bef A&D, lease adj | -2.3% -0.2% | 4.1% 5.7% | -4.1% -4.9% | 5.5% 5.0% | 4.2% 4.3% | 11.4% 11.7% | 11.9% 13.1% | -10.0% -10.1% | -17.3% -17.3% | 0.5% 0.5% | 4.0% 4.0% |

| BALANCE SHEET | | | | | | | | | | | |
|--|---------------------|---------------------|----------|-------|-------|--------|------------|----------------|------------------|--------|--------|
| SEKm | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | 2023E |
| Intangible assets | 195 | 259 | 155 | 138 | 121 | 104 | 114 | 253 | 285 | 297 | 310 |
| of which R&D | 164 | 224 | 147 | 132 | 117 | 100 | 100 | 120 | 120 | 120 | 120 |
| of which other intangibles | 4 | 7 | 8 | 6 | 5 | 4 | 14 | 133 | 165 | 177 | 189 |
| of which goodwill | 26 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tangible assets | 33 | 29 | 25 | 22 | 20 | 20 | 79 | 115 | 115 | 115 | 115 |
| of which leased assets | 0 | 0 | 0 | 0 | 0 | 0 | 57 | 68 | 68 | 68 | 68 |
| Shares associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest bearing assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred tax assets | 0 | 3 | 18 | 25 | 28 | 93 | 86 | 33 | 33 | 33 | 33 |
| Other non-IB non-current assets | 0 | 1 | 2 | 8 | 7 | 10 | 0 | 0 | 0 | 0 | 0 |
| Other non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Total non-current assets | 228 | 293 | 200 | 193 | 177 | 227 | 280 | 401 | 433 | 445 | 457 |
| Inventory | 383 | 488 | 403 | 344 | 250 | 174 | 132 | 108 | 101 | 120 | 137 |
| Accounts receivable | 36 | 142 | 168 | 179 | 218 | 296 | 273 | 218 | 208 | 247 | 281 |
| Short-term leased assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other current assets | 19 | 32 | 51 | 21 | 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash and bank | 106 | 285 | 198 | 282 | 328 | 590 | 817 | 505 | 254 | 259 | 311 |
| Total current assets | 544 | 946 | 820 | 826 | 827 | 1,060 | 1,221 | 831 | 563 | 626 | 730 |
| Assets held for sale | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 772 | 1,239 | 1,020 | 1,019 | 1,004 | 1,287 | 1,501 | 1,233 | 996 | 1,071 | 1,187 |
| Shareholders equity | 161 | 468 | 270 | 310 | 329 | 476 | 706 | 559 | 364 | 381 | 444 |
| Of which preferred stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Of which equity part of hybrid debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 161 | 468 | 270 | 310 | 329 | 476 | 706 | 559 | 364 | 381 | 444 |
| Deferred tax | 0 | 400 | 0 | 0 | 0 | 470 | 0 | 0 | 0 | 0 | 0 |
| Long term interest bearing debt | 104 | 494 | 494 | 398 | 319 | 321 | 290 | 0 | 225 | 225 | 225 |
| Pension provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other long-term provisions | 10 | 9 | 7 | 1 | 6 | 7 | 11 | 26 | 26 | 26 | 26 |
| Other long-term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-current lease debt | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 47 | 47 | 47 | 47 |
| Convertible debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholder debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hybrid debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total non-current liabilities | 114 | 503 | 501 | 399 | 325 | 327 | 334 | 73 | 298 | 298 | 298 |
| Short-term provisions | 0 | 0 | 122 | 164 | 201 | 266 | 269 | 197 | 188 | 223 | 255 |
| Accounts payable | 138 | 29 | 35 | 36 | 46 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current lease debt | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 19 | 19 | 19 | 19 |
| Other current liabilities | 359 | 239 | 92 | 110 | 104 | 218 | 171 | 160 | 127 | 150 | 171 |
| Short term interest bearing debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 225 | 0 | 0 | 0 |
| Total current liabilities | 497 | 268 | 249 | 310 | 350 | 483 | 461 | 601 | 334 | 392 | 445 |
| Liabilities for assets held for sale | 0 | 0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total liabilities and equity | 772 | 1,239 | 1,020 | 1,019 | 1,004 | 1,287 | 1,501 | 1,233 | 996 | 1,071 | 1,187 |
| Policies de la late de la late | | | | | | | | | | | |
| Balance sheet and debt metrics Net debt | 136 | 212 | 296 | 115 | -9 | -269 | -473 | -214 | 37 | 32 | -20 |
| of which lease debt | 0 | 0 | 290 | 0 | -9 | -209 | -473 55 | 67 | 67 | 67 | 67 |
| Working capital | -59 | 394 | 495 | 398 | 351 | 252 | 234 | 166 | 183 | 216 | 247 |
| Invested capital | 169 | 686 | 695 | 591 | 527 | 479 | 514 | 567 | 616 | 662 | 704 |
| Capital employed | 266 | 962 | 765 | 708 | 648 | 797 | 1,051 | 850 | 655 | 672 | 735 |
| ROE | -87.9% | -18.0% | -53.6% | 10.0% | 7.3% | 34.3% | 28.8% | -13.3% | -42.1% | 4.5% | 15.3% |
| ROIC | -86.8% | -4.6% | -19.3% | 6.4% | 8.1% | 15.0% | 29.1% | -13.3% | -42.1% -29.2% | 2.5% | 8.6% |
| ROCE | -86.8% -48.3% | -4.6% -4.0% | -19.3% | 7.0% | 8.1% | 13.3% | 19.8% | -2.9% -2.1% | -29.2% -29.0% | 3.0% | 10.6% |
| NOOL | -1 0.570 | -4 .0 /0 | - 10.070 | 7.070 | 0.070 | 10.070 | 13.070 | -∠.1/0 | -23.U/0 | 5.0 /0 | 10.070 |
| Net debt/EBITDA | n.m. | n.m. | n.m. | 1.6 | -0.1 | -2.3 | -2.1 | -11.4 | n.m. | 0.6 | -0.2 |
| Interest coverage | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. |
| Equity ratio | 20.9% | 37.8% | 26.5% | 30.5% | 32.8% | 37.0% | 47.1% | 45.3% | 36.6% | 35.6% | 37.4% |
| Net gearing | 83.9% | 45.2% | 109.7% | 37.2% | -2.7% | -56.5% | -66.9% | -38.3% | 10.2% | 8.3% | -4.6% |

| CASH FLOW STATEMENT | | | | | | | | | | | |
|-------------------------------------|--------|-------|--------|-------|-------|-------|-------|-------|-------|-------|-------|
| SEKm | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | 2023E |
| EBITDA (adj) for associates | -90 | -12 | -150 | 74 | 78 | 117 | 224 | 19 | -183 | 55 | 110 |
| Paid taxes | -2 | -4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net financials | -11 | -28 | -25 | -28 | -35 | -32 | -8 | -9 | 3 | 0 | 0 |
| Change in provisions | 6 | -1 | 119 | 37 | 42 | 66 | 8 | -57 | -9 | 35 | 31 |
| Change in other LT non-IB | 19 | -4 | -16 | -13 | -3 | -68 | 16 | 54 | 1 | 0 | 0 |
| Cash flow to/from associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends paid to minorities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other adj to reconcile to cash flow | 16 | 13 | 25 | -3 | 28 | 43 | 13 | -42 | 0 | 0 | 0 |
| Funds from operations (FFO) | -62 | -36 | -47 | 68 | 110 | 125 | 253 | -35 | -189 | 90 | 141 |
| Change in NWC | -201 | -452 | -62 | 89 | 36 | 117 | 38 | 52 | -17 | -34 | -31 |
| Cash flow from operations (CFO) | -263 | -487 | -109 | 156 | 147 | 242 | 291 | 17 | -206 | 56 | 110 |
| Capital expenditure | 251 | 739 | 3 | -91 | -85 | 0 | 0 | -190 | -67 | -47 | -47 |
| Free cash flow before A&D | -12 | 252 | -107 | 66 | 61 | 242 | 291 | -173 | -273 | 9 | 63 |
| Proceeds from sale of assets | 0 | 0 | 22 | 7 | 0 | 0 | 10 | 1 | 0 | 0 | 0 |
| Acquisitions | -108 | -72 | -4 | -1 | -2 | -6 | -36 | 0 | 0 | 0 | 0 |
| Free cash flow | -120 | 180 | -89 | 71 | 60 | 236 | 265 | -172 | -273 | 9 | 63 |
| Free cash flow bef A&D, lease adj | -12 | 252 | -107 | 66 | 61 | 242 | 291 | -173 | -273 | 9 | 63 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity issues / buybacks | 19 | 342 | 4 | 2 | 0 | 0 | 2 | -27 | 0 | 0 | 0 |
| Net change in debt | 0 | 0 | 0 | 0 | 0 | 0 | -56 | -84 | 0 | 0 | 0 |
| Other financing adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | -3 | -11 |
| Other non-cash adjustments | -22 | -343 | -1 | 11 | -14 | 26 | 16 | -28 | 0 | 0 | 0 |
| Change in cash | -123 | 179 | -86 | 84 | 46 | 262 | 227 | -312 | -251 | 6 | 52 |
| Cash flow metrics | | | | | | | | | | | |
| Capex/D&A | n.m. | n.m. | -14.1% | n.m. | n.m. | 0.0% | 0.0% | n.m. | n.m. | n.m. | n.m. |
| Capex/Sales | -58.5% | n.m. | -0.4% | 12.8% | 13.3% | 0.0% | 0.0% | 28.6% | 10.6% | 6.3% | 5.5% |
| Key information | | | | | | | | | | | |
| Share price year end (/current) | 164 | 136 | 63 | 38 | 41 | 59 | 63 | 50 | 46 | 46 | 46 |
| Market cap. | 5,214 | 4,431 | 2,164 | 1,300 | 1,428 | 2,071 | 2,221 | 1,720 | 1,578 | 1,578 | 1,578 |
| Enterprise value | 5,349 | 4,643 | 2,460 | 1,415 | 1,420 | 1,802 | 1,749 | 1,506 | 1,615 | 1,609 | 1,557 |
| Diluted no. of shares, year-end (m) | 31.8 | 32.7 | 34.5 | 34.6 | 34.7 | 35.2 | 35.4 | 34.4 | 34.3 | 34.3 | 34.3 |

Diluted no. of shares, year-end (m)

Source: Company data and Nordea estimates

Disclaimer and legal disclosures

Origin of the report

This publication or report originates from: Nordea Bank Abp, including its branches Nordea Danmark, Filial af Nordea Bank Abp, Finland, Nordea Bank Abp, filial i Norge and Nordea Bank Abp, filial i Sverige (together "Nordea") acting through their unit Nordea Markets.

Nordea Bank Abp is supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the branches are supervised by the European Central Bank and the Finnish Financial Supervisory Authorities in their respective countries.

Content of report

This report has been prepared solely by Nordea Markets

Opinions or suggestions from Nordea Markets credit and equity research may deviate from one another or from opinions presented by other departments in Nordea. This may typically be the result of differing time horizons, methodologies, contexts or other factors.

The information provided herein is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information contained herein has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision

Opinions or ratings are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioural technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts or ratings in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the report, provided that the relevant company/issuer is treated anew in such later versions of the report.

Validity of the report

All opinions and estimates in this report are, regardless of source, given in good faith, and may only be valid as of the stated date of this report and are subject to change without notice.

No individual investment or tax advice

The report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This report has been prepared by Nordea Markets as general information for private use of investors to whom the report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this report, it is recommendable to consult (without being limited to) one's financial, legal, tax, accounting, or regulatory advisor in any relevant jurisdiction.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her own appraisal of the tax and other financial merits of his/her investment.

Sources

This report may be based on or contain information, such as opinions, estimates and valuations which emanate from: Nordea Markets' analysts or representatives, publicly available information, information from other units of Nordea, or other named sources.

To the extent this publication or report is based on or contain information emanating from other sources ("Other Sources") than Nordea Markets ("External Information"), Nordea Markets has deemed the Other Sources to be reliable but neither Nordea, others associated or affiliated with Nordea nor any other person, do guarantee the accuracy, adequacy or completeness of the External Information.

Limitation of liability

Nordea or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this report. In no event will Nordea or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages (regardless of whether being considered as foreseeable or not) resulting from the information in this report.

Risk information

The risk of investing in certain financial instruments, including those mentioned in this report, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

Conflicts of interest

Readers of this document should note that Nordea Markets has received remuneration from the company mentioned in this document for the production of the report. The remuneration is not dependent on the content of the report.

Nordea, affiliates or staff in Nordea, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the report.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Nordea Markets are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of Nordea and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Nordea Markets that no link exists between revenues from capital markets activities and individual analyst remuneration. Nordea and the branches are members of national stockbrokers' associations in each of the countries in which Nordea has head offices. Internal rules have been developed in accordance with recommendations issued by the stockbrokers associations. This material has been prepared following the Nordea Conflict of Interest Policy, which may be viewed at www.nordea.com/miffid.

Distribution restrictions

The securities referred to in this report may not be eligible for sale in some jurisdictions. This report is not intended for, and must not be distributed to private customers in the UK or the US. This research report is intended only for, and may be distributed only to, accredited investors, expert investors or institutional investors in Singapore who may contact Nordea Bank, Singapore Branch of 138 Market Street, #09-01 CapitaGreen, Singapore 048946.

This publication or report may be distributed by Nordea Bank Abp Singapore Branch, which is subject to the supervision of the European Central Bank, the Finnish Financial Supervisory Authority and the Monetary Authority of Singapore.

This publication or report may be distributed in the UK to institutional investors by Nordea Bank Abp London Branch of 6th Floor, 5 Aldermanbury Square, London, EC2V 7AZ, which is under supervision of the European Central Bank, Finanssivalvonta (Financial Supervisory Authority) in Finland and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority in the United Kingdom. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request.

This report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws.

Analyst ShareholdingNordea Markets analysts do not hold shares in the companies that they cover. No holdings or other affiliations by analysts or associates

Fair value and sensitivity

We calculate our fair values by weighting DCF, DDM, SOTP, asset-based and other standard valuation methods. Our fair values are sensitive to changes in valuation assumptions, of which growth, margins, tax rates, working capital ratios, investment-to-sales ratios and cost of capital are typically the most sensitive. It should be noted that our fair values would change by a disproportionate factor if changes are made to any or all valuation assumptions, owing to the non-linear nature of the standard valuation models applied (mentioned above). As a consequence of the standard valuation models we apply, changes of 1-2 percentage points in any single valuation assumption can change the derived fair value by as much as 30% or more. All research is produced on an ad hoc basis and will be updated when the circumstances require it.

Marketing Material

This research report should be considered marketing material, as it has been commissioned and paid for by the subject company, and has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report. However, Nordea Markets analysts are according to internal policies not allowed to hold shares in the companies/sectors that they cover.

Market-making obligations and other significant financial interest

Nordea Markets has no market-making obligations in Orexo.

Investment banking transactions

In view of Nordea's position in its markets readers should assume that the bank may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services to the company/companies

Issuer Review

This report has not been reviewed by the Issuer prior to publication.

Completion Date

29 Jan 2021, 03:30 CET

| Nordea Bank Abp | Nordea Bank Abp, filial i Sverige | Nordea Danmark, Filial af Nordea Bank Abp, Finland | Nordea Bank Abp, filial i Norge |
|--------------------------------|-----------------------------------|---|---------------------------------|
| Nordea Markets Division, | Nordea Markets Division, | Nordea Markets Division, | Nordea Markets Division, |
| Research | Research | Research | Research |
| Visiting address: | Visiting address: | Visiting address: | Visiting address: |
| Aleksis Kiven katu 7, Helsinki | Smålandsgatan 17 | Grønjordsvej 10 | Essendropsgate 7 |
| FI-00020 Nordea | SE-105 71 Stockholm | DK-2300 Copenhagen S | N-0107 Oslo |
| Finland | Sweden | Denmark | Norway |
| Tel: +358 9 1651 | Tel: +46 8 614 7000 | Tel: +45 3333 3333 | Tel: +47 2248 5000 |
| Fax: +358 9 165 59710 | Fax: +46 8 534 911 60 | Fax: +45 3333 1520 | Fax: +47 2256 8650 |
| Reg.no. 2858394-9 | | | |
| Satamaradankatu 5 | | | |

Helsinki